Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention

Objective: To estimate the incidence of major adverse cardiovascular events (MACE) with genotype test-guided antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome. Methods: Patients who had undergone PCI for acute coronary syndrome as well a...

Full description

Bibliographic Details
Main Authors:	S. Ramesh, S. Socrates, M.A. Rajasekaran, N. Senguttuvan
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	Indian Heart Journal
Subjects:	Clopidogrel Antiplatelet Genotyping Coronary intervention
Online Access:	http://www.sciencedirect.com/science/article/pii/S001948322030225X

Similar Items

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Dual Antiplatelet Therapy in Coronary Artery Disease
by: Raghav Sharma, et al.
Published: (2020-08-01)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
by: Larisa H. Cavallari, et al.
Published: (2018-04-01)

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
by: Xiaojun Zhuo, et al.
Published: (2018-09-01)

Duration of antiplatelet therapy cessation before coronary artery bypass surgery: Relation with platelet count
by: Sushil Prakash Ambesh
Published: (2015-07-01)

Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study
by: Hua Yan, et al.
Published: (2020-06-01)

A cost-effectiveness and safety analysis of dual antiplatelet therapy comparing aspirin–clopidogrel to aspirin–ticagrelor in patients with acute coronary syndrome
by: Nafrialdi Nafrialdi, et al.
Published: (2018-12-01)

Impact of Implementing CYP2C19 Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China
by: Yi Zhang, et al.
Published: (2021-01-01)

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
by: Yijiang Zhou, et al.
Published: (2017-06-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
by: Gregorio Tersalvi, et al.
Published: (2020-07-01)

Antiplatelet Therapy in the Patient with Coronary Stent Undergoing Surgery and Dental Procedure
by: Noppadol Chamnarnphol
Published: (2011-04-01)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019-02-01)

Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia
by: Francisco José Fernández-Fernández, et al.
Published: (2017-10-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

Non-responsiveness to oral antiplatelet treatment
by: Rok Perme, et al.
Published: (2006-10-01)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
by: Jianyu Qu, et al.
Published: (2021-06-01)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
by: Verheugt Freek WA, et al.
Published: (2001-05-01)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

The choice of the P2Y12 receptors blocker in the treatment of a patient with acute coronary syndrome: practice of N.I. Pirogov city clinical hospital №1
by: M. R. Atabegashvili, et al.
Published: (2019-04-01)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
by: Xiujin Shi, et al.
Published: (2021-06-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

Antiplatelet resistance and thromboembolic complications in neurointerventional procedures
by: Thomas J Oxley, et al.
Published: (2011-12-01)

ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01)

Antiplatelet treatment and gastro-intestinal hemorrhage risk
by: D. V. Duplyakov
Published: (2005-08-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
by: Patel V, et al.
Published: (2014-09-01)

Oral Antiplatelet Therapy for Secondary Prevention of Non-Cardioembolic Ischemic Cerebrovascular Events
by: Leonardo De Luca, et al.
Published: (2021-04-01)

Review of Antiplatelet Therapy for the Management of Acute Coronary Syndromes
by: Ganesh Nallur Shivu
Published: (2016-10-01)

Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry
by: Fu-Tien Chiang, et al.
Published: (2014-11-01)

MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: N. F. Puchinian, et al.
Published: (2017-03-01)

ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
by: E. V. Konstantinova, et al.
Published: (2018-07-01)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
by: Hyun Goo Kang, et al.
Published: (2021-08-01)

Comorbid patient with GERD and cardiovascular disease receiving antiplatelet therapy. The possibilities of choosing a proton pump inhibitor on a case study
by: I. G. Pakhomova
Published: (2019-10-01)

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2019-01-01)